Purpose: Newly approved novel drugs in Europe receive a black triangle label to promote pharmacovigilance. With growing momentum for earlier drug approvals and reliance on realworld evidence, we studied if the black triangle label promotes more judicious prescribing.
purpose of the black triangle in Europe is not to influence prescribing, theoretically, such labeling could help those in greatest need access new drugs while limiting more widespread exposure until completion of more conclusive postmarketing studies. 8 Indeed, the Institute of Medicine recommended use of a black triangle-like label to promote greater safety of new medications in the US. 9 The recent passage of the US 21st Century Cures Act increases reliance on real-world evidence and could lead to earlier drug approvals based on less rigorous evidence. 10 Such a situation would make it even more critical to communicate to prescribers and patients alike the incompleteness of safety information for newly approved medicines. One prior study investigated the impact of risk evaluation and mitigation strategies on offlabel prescribing patterns of new drugs for a rare disease. 11 To our knowledge, no study has evaluated the impact of a more generic and broadly used label for new medication, including the black triangle, on prescribing rates and behaviors.
We studied whether presence of a black triangle could make prescribers more cautious, hypothesizing that prescribing rates would increase after a label's removal. We expected new drugs in wellestablished drug classes would preferentially be prescribed to patients in greatest need. Thus, we hypothesized that patients newly prescribed selective serotonin reuptake inhibitors (SSRIs) with a black triangle would be older and sicker (eg, with more severe, refractory disease) than patients starting the same SSRIs after a black triangle's removal. Furthermore, for newer, less established drug classes, and particularly lifestyle drugs such as phosphodiesterase type 5 inhibitors (PDE5Is), we expected a different form of caution with early prescribing, favoring patients at lower risk of complications. We therefore hypothesized that men newly prescribed PDE5Is with a black triangle would be older but less sick than men who began these drugs after the label's removal.
2 | METHODS
| Study design
To estimate the effects of removal of a black triangle on prescribing practices, we used an interrupted time-series (ITS) approach paired with a case-control design ( Figure S1 ). Interrupted time-series is a robust quasi-experimental design that evaluates the effects of time-limited interventions longitudinally. 12 Interrupted time-series compares levels and trends of outcomes across successive periods before and after interventions; in this study, the intervention was removal of a black triangle. The case-control design enabled comparison of individuals newly prescribed labeled drugs (cases) with first-time users of the same drug after the label's removal (controls). Secondarily, to understand influences of secular trends on prescribing, we compared people who started comparable, unlabeled drugs across the same two periods. Another secondary analysis compared people who began taking labeled drugs with contemporary new users of unlabeled comparator drugs ( Figure S1 ).
This study was approved by The Health Improvement Network (THIN) Scientific Review Committee (16THIN006) and deemed exempt for institutional review board review (#824432, University of Pennsylvania; Pro20160000100, Rutgers).
| Data source
The study used anonymized data from 1998 through 2014 in THIN, a population-representative database with electronic health records from approximately 6% of the UK population (>12 million individuals). 13 THIN contains practice-and patient-level data collected through routine clinical care from >600 general practices across the UK. Data include demographics, diagnoses, outpatient prescriptions, referrals, and laboratory results. The Health Improvement Network is a valid source for pharmacoepidemiologic research 14 and has been used to study policy interventions using ITS. 15 
| Subject selection
Eligible subjects were registered in THIN practices with Vision software and had ≥183 days of baseline data. We focused on individuals who received first-ever prescriptions for escitalopram, tadalafil, vardenafil (drugs of interest), or comparable drugs from the same class-SSRIs or PDE5Is, respectively (Table S1 ). Drugs of interest were selected from medicines marketed in the UK whose black triangles were added or removed between 2000 and 2010 (Supplementary Methods). Analyses of PDE5Is excluded females, children, and people diagnosed with pulmonary hypertension to focus on the use of PDE5Is to treat erectile dysfunction.
The preselected primary comparators for escitalopram were citalopram and fluoxetine. These were longstanding SSRIs, one a structurally similar medication from the same manufacturer (citalopram) and both available in generic form when escitalopram was approved. Secondarily, we examined a comparator, sertraline, that went off patent during the study period. The preselected primary comparator for tadalafil and vardenafil was sildenafil, the only other approved PDE5I, whose black triangle had been removed over 1 year before tadalafil and vardenafil were approved.
| Independent variables
The primary independent variable for ITS analysis was presence of a black triangle. 
KEY POINTS
• The black triangle label for newly approved drugs does not appear to promote judicious prescribing.
• Market forces have more impact on prescribing than the black triangle.
• People who initiate black triangle drugs are different from new users of the same drugs after the label's removal, but these differences reflect secular trends.
| Outcomes
The primary outcomes were the levels and changes of monthly new Figure S1 ; Table S1 ).
| Statistical analysis
We used descriptive statistics to summarize the rates of new drug prescribing during the black triangle period studied and a corresponding interval after a black triangle's removal. To estimate changes in levels and trends of first-time prescribing between periods during and after a black triangle, ITS data were analyzed using ordinary least-squares segmented regression adjusted for autocorrelation. 16 Other analyses studied additional periods after patents for comparators expired (eg, sertraline and sildenafil) (Table S1) (Table 2 ; Figure 1C ). After the label's removal, however, sildenafil was prescribed at slightly higher levels. When generic sildenafil became available, GPs prescribed sildenafil at high and increasing rates while new prescribing of tadalafil and vardenafil declined sharply ( Figure 1D ).
In secondary analyses, new prescribing declined more within 2 years after removal of black triangles than in subsequent years (Tables S2 and S3 ). In sensitivity analyses that assumed premature removal of labels or excluded 6 months after label removal, results
were similar (Tables S4 and S5 ).
| Characteristics of individuals prescribed drugs with and without a black triangle label
When we compared patients newly prescribed escitalopram before and after removal of the black triangle, individuals prescribed labeled escitalopram were less likely to be children or elderly or to have multiple comorbidities or recent hospitalization (Table 3; Table S6 ). There were similar differences across periods among those newly prescribed citalopram and fluoxetine. In comparing contemporary new users of labeled escitalopram and unlabeled citalopram or fluoxetine, we found those starting escitalopram were less likely to be children, more likely to take multiple other medications, and more likely to have a previously diagnosed mood disorder and receive prior SSRIs. People who began labeled or unlabeled SSRIs did not significantly differ in number of comorbidities. (Table 4; Table S7 ). Men who started taking labeled tadalafil or vardenafil were also more likely to have diabetes mellitus (related comorbidity) and cardiovascular disease (relative contraindication)
than new users in the postlabel era. As we found with SSRIs, there were similar differences between new users of sildenafil across the same eras, with overlapping confidence intervals for all variables (Table 4 ). Similar differences were also seen between new users of sildenafil before and after removal of its own black triangle, except that men who started labeled sildenafil were less likely to take multiple ORs were generated using generalized estimating equations with the same prespecified covariate set consisting of the variables shown, local measures of deprivation (Townsend scores), and the size and country of the general practice.
b Measured 1 to 183 days before the respective case/control period.
other medications or have previously diagnosed erectile dysfunction.
When we compared individuals starting labeled tadalafil or vardenafil with those beginning unlabeled sildenafil in the same era, men who began labeled drugs were less likely to be under age 40 and take multiple medications and more likely to have diabetes and prior erectile dysfunction. As with SSRIs, we saw no significant differences in comorbidity burden between men who began labeled or unlabeled PDE5Is.
In sensitivity analyses that included new users of multiple drugs only once, the findings did not substantially change ( Figures S3 and S4 ).
| DISCUSSION
In contrast to our expectations, we found that newly approved drugs labeled with a black triangle were not prescribed at lower rates that increased over time. In fact, GPs prescribed new drugs from 2 drug classes at the highest levels shortly after their initial approval and at lower rates in subsequent years. The removal of a black triangle was not associated with an increased rate of prescribing but rather with no changes (PDE5Is) or declines (escitalopram) in the rates of new prescriptions. Furthermore, new generic availability of comparable drugs corresponded with more dramatic differences in prescribing than removal of black triangle labels. These findings suggest that market forces play a larger role in prescribing rates than black triangle labeling. When comparing characteristics of individuals newly prescribed drugs over time, we expected to find numerous differences, depending on whether medicines had a change in labeling (ie, removal of a black triangle) and on clinicians' familiarity with drug classes (ie, well-established SSRIs vs newer PDE5Is). However, our findings were similar for drugs in these two disparate drug classes irrespective of the black triangle label. We did find some modest clinical differences between individuals starting older drugs and those starting recently approved drugs with a black triangle. Nonetheless, it remains unclear whether these differences in prescribing reflected drugs' relative "newness" or presence of a black triangle.
The black triangle has been used in the UK Yellow Card Scheme and subsequently in the EU to promote pharmacovigilance and ADE reporting for new medical products. 4 Earlier studies showed that systematic implementation and notification of these schemes increased ADE reporting. 17, 18 However, subsequent studies suggested somewhat limited impact of a black triangle label on new drug monitoring.
In surveys, only half to two-thirds of physicians recognized the black triangle as a label for new medications. 19, 20 Furthermore, general practitioners consistently underreported ADEs associated with black triangle medications, including up to 90% of minor events and one-quarter to one-half of serious events. 5, 6 One study identified several factors associated with lower rates of ADE reporting among GPs, including higher numbers of patients seen and prescriptions written. 21 At one time, approximately one-quarter of drugs assigned with a black triangle label lacked the symbol in official product information. 22 The 21st Century Cures Act could lead to broad, accelerated drug approvals in the US based on less substantive levels of evidence of efficacy or safety. 10 With such a shift in regulation and increasing reliance on real-world evidence, it would be increasingly critical for clinicians and the public to recognize which novel drugs were recently approved and had incomplete safety information. Even before the passage of this new legislation, we and others have advocated for the use of labeling schemes similar to the black triangle for newly approved medicines in the US. 8, 23 Such labeling for recently approved drugs in the US might not only raise awareness about the uncertainty of their safety but also promote more judicious prescribing channeled to patients with the greatest need and, thus, the highest benefit-risk ratio. 8 Indeed, the Institute of Medicine recommended the use of a black triangle-like label to promote greater safety of new medications. 9 Notably, the FDA declined this recommendation because of concerns that such a label could be confusing to and misinterpreted by prescribers and patients and that adequate systems were already in place to communicate the "newness" of recently approved drugs and devices. 24 Our findings support the conclusion that a black triangletype label may not substantially limit prescribing in practice. These results contrast with other studies showing that changes in drug labeling in "response" to new safety information can affect prescribing behavior. 25, 26 Other studies have also shown the relatively greater impact of market forces compared with drug regulation alone. 27 Our study has several strengths. We leveraged routinely collected population-representative health care data to evaluate the impact of a longstanding label for new drugs on use and prescribing. Interrupted time-series analyses with unexposed comparators have strong internal validity by controlling for confounding and secular trends, making them particularly useful in studying the impact of policies on drug use. 28, 29 Furthermore, the case-control studies permitted understanding of a black triangle's impact on prescribing at the individual level. Sensitivity analyses suggested that our findings were robust to various assumptions. Finally, this study is novel and has important implications for policy makers in the US, Europe, and elsewhere.
This study also has certain limitations. We focused on effects of black triangle labeling on drug prescribing from two classes first approved over a decade ago. Our findings may not apply to more recent approvals across the EU or to prescribing of other types of medication (eg, chemotherapies, biologics, and vaccines). Furthermore, because we found some minor clinical differences between people prescribed drugs with a black triangle and similar drugs without a black triangle, we cannot rule out the possibility that the label affects prescribing behaviors at least to some degree.
Labeling of newly approved drugs with a black triangle is not associated with more limited prescribing among general practitioners.
Economics (eg, drug marketing and cost) appears to have a larger impact on prescribing trends than a black triangle label. With the passage of the 21st Century Cures Act, accelerated drug approvals could lead to more uncertainty about the effectiveness and safety of new drugs in the future. However, labeling of newly approved medicines in the fashion of the black triangle is unlikely to promote more judicious prescribing.
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